Anavex Life Sciences Corp (AVXL)

[Amatuer17]

According to Associate professor Steve Macfarlane, who has been overseeing the trial at Melbourne’s Caulfield Hospital as part of the global study, the preliminary response by Lawler has been “incredible.” Macfarlane noted a clear improvement in Lawler’s memory, saying Lawler is a “poster child for success in clinical trials.”

The IMAGINE trial is a 12-month, double-blind study where patients are administered PBT2 once per day and tested once per month for any effect.

Macfarlane said that the drug seems to have slowed the progression of the disease by about 30 percent in patients with mild Alzheimer’s compared to placebo.

For their part, Prana issued a statement on Friday saying that the company was not aware of the segment and did not participate in it. “The clinical benefit, if any, of PBT2 compared to a placebo will not be known until treatment assignment is un-blinded and the trial data analysed,” Prana said in the release.